نفازودون
Sign in to saveAlso known as BMY-13754, MJ-13754-1, 1-{3-[4-(m-chlorophenyl)-1-piperazinyl]propyl}-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one
Nefazodone, sold formerly under the brand names Serzone, Dutonin, and Nefadar among others, is an atypical antidepressant medication which is used in the treatment of depression and for other uses. Nefazodone was withdrawn in most countries by 2004 (due to liver toxicity). On December 2021, it was published that despite shortage it is still available in the United States.As of February 2026 it is available in the United States in generic form. The medication is taken by mouth.
Research
829 papers- Nefazodone.2012
- Nefazodone: a new antidepressant.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 1995
- Nefazodone: its place among antidepressants.The Annals of pharmacotherapy · 1996
- Clinical pharmacokinetics of nefazodone.Clinical pharmacokinetics · 1997
- Nefazodone-induced mania.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 1995
via PubMed
Wikidata facts
- Mass
- 469.224
Show 5 more facts
- chemical formula
- C₂₅H₃₂ClN₅O₂
- canonical SMILES
- CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
- World Health Organisation international non-proprietary name
- nefazodone
- defined daily dose
- 0.4
- Commons category
- Nefazodone
Sources (6)
via Wikidata · CC0
Connections
propranolol
Entity
adrenergic receptor
Entity
N-methylserotonin
Entity
antidepressant
Entity
pharmacokinetics
Entity
histamine antagonist
Entity
biological half-life
Entity
atenolol
Entity
monoamine oxidase inhibitor
Entity
tricyclic antidepressant
Entity
labetalol
Entity
serotonin–norepinephrine reuptake inhibitor
Entity
ergoline
Entity
liver disease
Entity
(Z)-thiothixene
Entity
DRD2
Gene
Histamine receptor H1
Protein
levobunolol
Entity
tetracyclic antidepressant
Entity
glaucine
Entity
Categories
1,2,4-Triazol-3-ones1-Phenylpiperazines3-Chlorophenyl compounds5-HT1A agonists5-HT2A antagonists5-HT2C antagonistsAlpha-1 blockersAlpha-2 blockersAntidepressantsAnxiolyticsCYP3A4 inhibitorsDrugs with non-standard legal statusH1 receptor antagonistsHepatotoxinsPhenol ethersSerotonin–norepinephrine–dopamine reuptake inhibitorsUreasWithdrawn drugs